Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
2020 10.1016/j.breast.2020.09.008

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Fasching et al., The Breast 54 (2020) 148-154

Study Summary: This dashboard visualizes Health-Related Quality of Life (HRQOL) outcomes from the MONALEESA-3 study comparing Ribociclib + Fulvestrant vs. Placebo + Fulvestrant in advanced breast cancer. Key metrics include Time to Definitive Deterioration (TTD) and baseline scores.

Drag

Study Design & Arms

Total N=726Ribociclib + fulvestrantn = 484Ribociclib (600 mg/day; 3 weeks on/1 wee...Placebo + fulvestrantn = 242Placebo + fulvestrantRandomization 2:1
Drag

Time to Deterioration (Hazard Ratios)

Comparing Ribociclib vs. Placebo. HR < 1 favors Ribociclib.

0.40.60.81.01.21.4Global Health StatusBPI-SF pain severity indexPhysical FunctioningEmotional FunctioningNo Difference (HR=1)← Favors Ribociclib0.81 [95% CI, 0.62–1.1]0.77 [95% CI, 0.57–1.05]0.82 [95% CI, 0.61–1.10]0.76 [95% CI, 0.57–1.01]
Drag

Baseline Global Health Status

Mean scores (0-100) at baseline. Higher is better.

Ribociclib + fulvestrantPlacebo + fulvestrant02040608010065.568.4
Drag

Risk Reduction Magnitude

Calculated as (1 - HR) * 100. Shows % reduction in risk of deterioration.

Global Health StatusBPI-SF pain severity indexPhysical FunctioningEmotional Functioning0%2%4%6%8%10%12%14%16%18%20%22%24%26%28%30%19.0%23.0%18.0%24.0%
Drag

Pain Severity (BPI-SF) Detail

Focus on Pain Severity Index (M02). Visualizing the confidence interval spread.

0.40.50.60.70.80.91.01.11.2Hazard Ratio: Pain Severity Index1.0 (No Effect)0.77NaN5
Drag

Sample Size Distribution

Total N=726 randomized 2:1.

484242Ribociclib + fulvestrantPlacebo + fulvestrant
Drag

Appendix: Raw Data & Sources

Metric Group Value Unit Provenance
Hazard Ratio for TTD ≥10% in Global Health Status Ribociclib + fulvestrant 0.81 [95% CI, 0.62–1.1] HR P01
Hazard Ratio for TTD ≥10% in BPI-SF pain severity index Ribociclib + fulvestrant 0.77 [95% CI, 0.57–1.05] HR P01
Baseline Global Health Status Score Ribociclib + fulvestrant 65.5 (19.1) Score (0-100) P02
Baseline Global Health Status Score Placebo + fulvestrant 68.4 (18.5) Score (0-100) P02
Hazard Ratio for TTD ≥10% in Physical Functioning Ribociclib + fulvestrant 0.82 [95% CI, 0.61–1.10] HR P03
Hazard Ratio for TTD ≥10% in Emotional Functioning Ribociclib + fulvestrant 0.76 [95% CI, 0.57–1.01] HR P03

Provenance Index

  • P01: Abstract Results (Page 1) - "HR for TTD ≥10% = 0.81 [95% CI, 0.62–1.1]... TTD ≥10% in BPI-SF pain severity index score (HR = 0.77 [95% CI, 0.57–1.05])"
  • P02: Table 1 (Page 2) - "Ribociclib + fulvestrant Baseline (n=447) 65.5 (19.1)... Placebo + fulvestrant Baseline (n=224) 68.4 (18.5)"
  • P03: Page 3 Results (Page 3) - "HR = 0.82 [95% CI, 0.61–1.10]... for the physical functioning score... HR = 0.76 [95% CI, 0.57–1.01]... for the emotional functioning score"
Drag
New container
Drag
New container
Drag
New container
Drag
👀 View Mode